Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population

References

• Guevara J, Lozano P, Wickizer T, et al. Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder. Pediatrics 2001;108:71-8
   PubMed Web of Science ®Google Scholar
• Cohen P, Cohen J, Kasen S, et al. An epidemiological study of disorders in late childhood and adolescence – I. Age- and gender-specific prevalence. J Child Psychol Psychiatry 1993;34:851-67
   PubMed Web of Science ®Google Scholar
• Gomez-Beneyto M, Bonet A, Catala MA, et al. Prevalence of mental disorders among children in Valencia, Spain. Acta Psychiatr Scand 1994;89:352-7
   PubMed Web of Science ®Google Scholar
• Breton JJ, Bergeron L, Valla JP, et al. Quebec child mental health survey: prevalence of DSM-III-R mental health disorders. J Child Psychol Psychiatry 1999;40:375-84
   PubMed Web of Science ®Google Scholar
• Fayyad J, De GR, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007;190:402-9
   PubMed Web of Science ®Google Scholar
• Searight HR, Burke JM, Rottnek F. Adult ADHD: evaluation and treatment in family medicine. Am Fam Physician 2000;62:2077-2
   PubMed Web of Science ®Google Scholar
• Faraone SV, Sergeant J, Gillberg C, et al. The worldwide prevalence of ADHD: is it an American condition?. World Psychiatry 2003;2:104-13
   PubMedGoogle Scholar
• Taylor E, Dopfner M, Sergeant J, et al. European clinical guidelines for hyperkinetic disorder – first upgrade. Eur Child Adolesc Psychiatry 2004;13(Suppl. 1):I/7-I/30
   Google Scholar
• World Health Organization. ICD-10: International Statistical Classification of Diseases and Related Health Problems, 10th Revision. Geneva: World Health Organization, 1994
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders DSM-IV-TR, 4th Edn. American Psychiatric Publishing, Inc., 2000
   Google Scholar
• Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007;164:942-8
   PubMed Web of Science ®Google Scholar
• Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005;366:237-48
   PubMed Web of Science ®Google Scholar
• Wolraich ML. Attention-deficit hyperactivity disorder. Semin Pediatr Neurol 2006;13:279-85
   PubMedGoogle Scholar
• Spencer TJ. ADHD and comorbidity in childhood. J Clin Psychiatry 2006;67(Suppl. 8):27-31
   PubMed Web of Science ®Google Scholar
• Brown RT, Amler RW, Freeman WS, et al. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence. Pediatrics 2005;115:e749-e757
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Attention deficit hyperactivity disorder: NICE clinical guideline 72. NICE, 2008. Available at: http://www.nice.org.uk/nicemedia/pdf/CG072NiceGuidelinev4.pdf [Last accessed 20 January 2010]
   Google Scholar
• Greydanus DE, Pratt HD, Patel DR. Attention deficit hyperactivity disorder across the lifespan: the child, adolescent, and adult. Dis Mon 2007;53:70-131
   PubMed Web of Science ®Google Scholar
• Kessler RC, Adler LA, Barkley R, et al. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: zresults from the national comorbidity survey replication. Biol Psychiatry 2005;57:1442-51
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics Subcommittee on Attention-Deficit/Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 2001;108:1033-44
   PubMed Web of Science ®Google Scholar
• Zuvekas SH, Vitiello B, Norquist GS. Recent trends in stimulant medication use among U.S. children. Am J Psychiatry 2006;163:579-85
   PubMed Web of Science ®Google Scholar
• Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46:894-921
   PubMed Web of Science ®Google Scholar
• Detail-document #220214: Drug treatment for attention deficit hyperactivity disorder. Pharmacist's Letter/Prescriber's Letter 2006;22:220214
   Google Scholar
• Adler LA, Spencer TJ, Williams DW, et al. Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. J Atten Disord 2008;12:248-53
   PubMed Web of Science ®Google Scholar
• Capp PK, Pearl PL, Conlon C. Methylphenidate HCl: therapy for attention deficit hyperactivity disorder. Expert Rev Neurother 2005;5:325-31
   PubMedGoogle Scholar
• Barbaresi WJ, Katusic SK, Colligan RC, et al. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study. J Dev Behav Pediatr 2006;27:1-10
   PubMed Web of Science ®Google Scholar
• Pelham WE, Aronoff HR, Midlam JK, et al. A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder. Pediatrics 1999;103:e43
   PubMed Web of Science ®Google Scholar
• Adler LA, Goodman DW, Kollins SH, et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2008;69:1364-73
   PubMed Web of Science ®Google Scholar
• Health insurance portability and accountability act of 1996. Public law 104-191, 104th Congress. U S Department of Health & Human Services, 1996. Available at: http://www.cms.hhs.gov/HIPAAGenInfo/Downloads/HIPAALaw.pdf [Last accessed 12 January 2010]
   Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
   PubMed Web of Science ®Google Scholar
• Habel LA, Schaefer CA, Levine P, et al. Treatment with stimulants among youths in a large California health plan. J Child Adolesc Psychopharmacol 2005;15:62-7
   PubMed Web of Science ®Google Scholar
• Ramos-Quiroga JA, Bosch R, Castells X, et al. Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate: a chart review of Spanish adults with attention-deficit hyperactivity disorder. CNS Drugs 2008;22:603-11
   PubMed Web of Science ®Google Scholar
• Marcus SC, Wan GJ, Kemner JE, et al. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2005;159:572-8
   PubMed Web of Science ®Google Scholar
• Sanchez RJ, Crismon ML, Barner JC, et al. Assessment of adherence measures with different stimulants among children and adolescents. Pharmacotherapy 2005;25:909-17
   PubMed Web of Science ®Google Scholar
• Perwien A, Hall J, Swensen A, et al. Stimulant treatment patterns and compliance in children and adults with newly treated attention-deficit/hyperactivity disorder. J Manag Care Pharm 2004;10:122-9
   PubMedGoogle Scholar
• Olfson M, Marcus S, Wan G. Stimulant dosing for children with ADHD: a medical claims analysis. J Am Acad Child Adolesc Psychiatry 2009;48:51-9
   PubMed Web of Science ®Google Scholar
• Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002;41:26S-49S
   PubMed Web of Science ®Google Scholar